Covalon Technologies Ltd. (OTCMKTS:CVALF) Sees Large Decline in Short Interest

Covalon Technologies Ltd. (OTCMKTS:CVALF) was the target of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 100 shares, a decrease of 92.3% from the December 31st total of 1,300 shares. Based on an average trading volume of 20,700 shares, the short-interest ratio is currently 0.0 days.

Covalon Technologies Trading Down 0.5 %

OTCMKTS CVALF opened at $2.13 on Wednesday. The company has a market cap of $58.36 million, a P/E ratio of 30.86 and a beta of -0.27. The company has a fifty day simple moving average of $2.39 and a 200 day simple moving average of $2.25. Covalon Technologies has a 12-month low of $0.74 and a 12-month high of $3.08.

Covalon Technologies (OTCMKTS:CVALF) last issued its quarterly earnings data on Tuesday, January 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Covalon Technologies had a net margin of 8.58% and a return on equity of 12.33%.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.